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Aims of study. Present study investigated the eﬀect of Ecklonia cava (EC) on intestinal glucose uptake and insulin secretion. Mate-
rials and methods. Intestinal Na+-dependent glucose uptake (SGU) and Na+-dependent glucose transporter 1 (SGLT1) protein ex-
pression was determined using brush border membrane vesicles (BBMVs). Glucose-induced insulin secretion was examined in
pancreaticβ-isletcells.TheantihyperglycemiceﬀectsofEC,SGU ,andSGL T1expr essionwer edeterminedinstr eptozotocin(STZ)-
induced diabetic mice. Results. Methanol extract of EC markedly inhibited intestinal SGU of BBMV with the IC50 value of
345μg/mL. SGLT1 protein expression was dose dependently down regulated with EC treatment. Furthermore, insulinotrophic ef-
fect of EC extract was observed at high glucose media in isolated pancreatic β-islet cells in vitro.W en e x tc o n d u c t e dt h ea n t i -
hyperglycemic eﬀect of EC in STZ-diabetic mice. EC supplementation markedly suppressed SGU and SGLT1 abundance in BBMV
fromSTZmice.Furthermore,plasmainsulinlevelwasincreasedbyECtreatmentindiabeticmice.Asaresult,ECsupplementation
improvedpostprandialglucoseregulation,assessedbyoralglucosetolerancetest,indiabeticmice.Conclusion.Theseresultssuggest
thatECplayaroleincontrollingdietaryglucoseabsorptionattheintestineandinsulinotrophicactionatthepancreascontributing
blood glucose homeostasis in diabetic condition.
1.Introduction
Diabetes is one of the most prevalent and serious metabolic
diseases worldwide. It is characterized by chronic hypergly-
cemia, impairment of insulin secretion from pancreatic β-
cells, and insulin resistance in peripheral tissues. One of the
therapeutic approaches for decreasing postprandial hyper-
glycemia is to retard the absorption of glucose by inhibition
of carbohydrate-hydrolyzing enzymes such as α-amylase and
α-glycosidase. However, they are not able to prevent glucose
absorption when glucose itself has been ingested. Hence, the
directinhibitionofintestinalglucoseabsorptioncouldrepre-
sent a novel mechanism for an antidiabetic drug.
Intestinal glucose absorption is thought to be regulated
by the Na+-dependent glucose transporter 1(SGLT1) at the
apical membrane of the intestinal epithelia [1]. It has been
shown in diabetic animals and humans that the capacity of
the small intestine to absorb glucose increases at the brush
border membrane vesicles (BBMVs) due to the enhanced
activity and abundance of SGLT1 [2, 3].
In order to prevent or delay the progression of diabetes,
insulin should be suﬃciently secreted to compensate for in-
sulin resistance in peripheral tissues. Thus, one of the mech-
anisms for the antidiabetic agents requires the characteristics
of insulinotrophic action from pancreatic cells [4].
Marinealgaehavebeenidentiﬁedasrichsourcesofstruc-
turallydiversebioactivecompoundswithgreatpharmaceuti-
cal and biomedical potential. The brown algae, Ecklonia cava
(EC), are abundant in the south-west coastal region of Japan
andKorea.IthasbeenreportedthatECextracthasnumerous
biological activities including antioxidative, radical scaveng-
ing,immunomodulatory,andantimutagenicactivities[5–8].
Recently, Lee et al. demonstrated that polyphenol isolated
from EC inhibit α-amylase and α-glycosidase activities and
alleviate postprandial hyperglycemia in streptozotocin-
(STZ-) induced diabetic mice [9]. However, the eﬀect of EC
on intestinal glucose uptake or insulinotrophic action has
not been examined. In this study, we investigated the eﬀects
of EC on intestinal Na+-dependent glucose uptake, SGLT1
protein expression, and insulin secretion in pancreatic islets.2 Evidence-Based Complementary and Alternative Medicine
Furthermore, the antihyperglycemic eﬀects of EC in STZ-
induced diabetic mice were also evaluated.
2. MaterialsandMethods
2.1. Preparation of EC Powder and Extract. EC was obtained
from a local market in Seosan, Republic of Korea. Fresh EC
was washed, dried, and ground into powder. The EC powder
was used for the in vivo experiment, and EC extract was used
for the in vitro experiment. The dried powder was extracted
three times with ten volumes of methanol at room tempera-
tur efor24hour .Thec ombinedextractswer ecentrifuged,ﬁl-
tered,concentratedundervacuum,lyophilized,concentrated
to 1mg/mL with deionized water, and subsequently used for
the experiment.
2.2. BBMV Isolation. BBMVs were prepared using a previ-
ously described method with some modiﬁcation [10]. All
subsequent isolation steps were performed at 4◦C. Male ICR
mice (8-week old, Joongang Lab Animal Co., Korea) jejunal
mucosal scrapings were suspended in 10mM HEPES/Tris
buﬀer (pH 7.5), containing 300mM mannitol and 300mM
MgCl2, and homogenized in a glass-Teﬂon homogenizer
(Glass-Col, Terre Haute, IN, USA) for 2min at 3,000rpm.
The mixture was stirred for 2min and centrifuged at
15,000rpm for 15min at 4◦C. The supernatant was centri-
fuged at 30,000rpm for 45min. The resulting pellets were
resuspended in 10mM HEPES/Tris buﬀer containing
300mM mannitol (pH 7.5) to a ﬁnal protein concentration
of10mg/mLandstoredinliquidnitrogenuntiluse.Thedeg-
ree of purity in BBMV was routinely assessed by the enrich-
ment of alkaline phosphatase (ALP) in the ﬁnally prepared
BBMV compared to the homogenate of intestinal scrapings.
ALP activity was determined with ALP assay kit (Yeongdong
Pharmaceutical Co., Seoul, Korea). The speciﬁc ALP activ-
ities of mucosal homogenate and BBMV suspension were
1.21 ± 0.09 and 6.21 ± 0.48 units/mg protein, respectively,
exhibiting 5-fold enrichment in ﬁnal BBMV fraction. The
amount of protein in the BBMV was measured by the Brad-
ford method [11].
2.3. Na+-Dependent Glucose Uptake. Measurement of Na+-
dependent glucose uptake by BBMV was determined by in-
cubating150μLBBMVsuspensionwith850μLuptakebuﬀer
containing 100μM 2-NBDG (Molecular Probes, Grand
Island, NY, USA) and EC extract (0.1mg/mL) at 37◦Cf o r
15min in a shaking water bath. The uptake reaction was
stopped by centrifuging for 20min at 15,000rpm, and the
B B M Vp e l l e tw a sw a s h e dw i t hs t o pb u ﬀer. The uptake and
stop buﬀers were 10mM HEPES/Tris (pH 7.5) containing
150mM NaCl and 300uM phlorizin (Sigma Co., St. Louis,
USA), respectively. Glucose uptake was measured by detect-
ingﬂuorescenceintensityof2-NBDGwithaspectroﬂuorom-
eter (excitation: 485nm, emission: 535nm). The diﬀerence
between the glucose uptakes in the presence of Na+ and
phlorizin represents the Na+-dependent glucose uptake by
SGLT1.
2.4. SGLT1 Expression. Glutaraldehyde was added to Im-
mune well plate and incubated at 37◦Cf o r1h o u r .A f t e r
washing the plate, an antigen of diluted BBMV membrane
protein (100μL/well) and EC were added and incubated at
37◦C for 2 hours. After washing the plate, the coated plates
were blocked with blocking solution (0.5% casein) at 37◦C
for 1 hour. Primary antibody incubation was conducted with
100μL of the SGLTI polyclonal antibody (Chemicon Inter-
national Inc., Temecula, CA, USA; diluted 1:1000 in 0.5%
casein) at 37◦C for 2 hour. Secondary antibody incubation
was conducted with 100μL of the anti-rabbit IgG conjugated
to horseradish peroxidase (diluted 1:2000 in 0.5% casein) at
37◦Cfor1hour.Forsubstrateincubation,200μLofsubstrate
solution (TMB 10mg/L DMSO, 3% H2O2,5 0m Ms o d i u m
acetate buﬀer,pH 5.1) was added to each well and reacted for
15min. The enzymatic reaction was stopped by adding 50μL
of 1M H2SO4 to each well. The absorbance was determined
at 450nm using automated microplate reader (Model 550,
BIO-RAD Laboratories, Philadelphia, PA, USA).
2.5.InsulinSecretion. Pancreaticisletcellswereisolatedfrom
male mice by collagenase digestion [12]. Twenty islets were
preincubated in Krebs-Ringer the bicarbonate (KRB) buﬀer,
pH 7.4, supplemented with serum albumin (3mg/mL) and
glucose(3mM)for30minat37 ◦C under humidiﬁed atmos-
phere of 5% CO2. The islets were treated with EC extract
(50μg/mL)in3,8,and16mMglucoseKRBbuﬀerfor60min
at 37◦C. Insulin concentration in each medium was deter-
mined using an ELISA procedure (Boehringer Mannheim
Diagnostics, Germany).
2.6. Animal Study. Male ICR mice (8-week old) were hous-
ed in plastic cages under temperature- (24 ± 2◦C) and light-
(12-hour light/dark cycle) controlled conditions with con-
stant humidity (55 ± 5 % ) .T h es t u d yh a sb e e nc a r r i e do u t
along the Korea National Institutes of Health Guidelines on
the care and use of laboratory animals and approved by
Hanseo University. The mice were randomly divided into
four groups (n = 1 0 ) ;n o r m a lc o n t r o l( N C ) ,n o r m a lm i c e
fed EC powder (NE), diabetic control (DC), and diabetic
mice fed EC powder (DE). Normal and diabetic control mice
were fed AIN-93-based semipuriﬁed standard diet, and ex-
perimental groups were supplemented with EC powder (3%,
w/w). Diabetes was induced by a single intraperitoneal injec-
tion of STZ (Sigma, St. Louis, USA; 95mg/kg in citrate buf-
fer, pH 4.5). NC group received the buﬀer only. Tail bleeds
were performed 24 hour after injection, and animals with
blood glucose concentrations above 300mg/dL were consid-
ered to be diabetic and used in this study.
2.7. Oral Glucose Tolerance Test and Intestinal BBMV Glucose
Uptake. At the end of 4 weeks of experimental period, mice
were fasted overnight and administered with glucose
(1.5g/kg). Blood samples were collected from the tail at vari-
ous time points (0∼90min) after glucose loading, and blood
glucose levels were measured by one-touch basic glucose
measurement system (Lifescan Inc., Milpitas, CA, USA).
Mice were killed by decapitation immediately after 90-minEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Eﬀects of Ecklonia cava (EC) on Na+-dependent glucose uptake and SGLT1 expression. (a) Time course eﬀects. ∗Eﬀect of EC
(100μg/mL) at P<0.05. (b) Concentration-dependent inhibitory eﬀects. Data are expressed as the % of inhibitory activity compared to
control group. Glucose uptake was measured with 150mM NaCl or 300μM phlorizin to evaluate the sodium dependency of the glucose
uptake. (c) Downregulation of SGLT1 expression by EC treatment. SGLT1 abundance was determined by ELISA analysis. a–cDiﬀerent letters
are signiﬁcantly diﬀerent at P<0.05. Each value is the mean ± SE of three diﬀerent experiments.
blood samples were taken. Preparation of intestinal BBMV,
Na+-dependent glucose uptake, and plasma insulin concen-
trations were determined as described above.
2.8.StatisticalAnalysis. Resultswerepresentedasmean±SE,
and signiﬁcant diﬀerences (P<0.05) between groups were
analyzed by ANOVA followed by Tukey’s post hoc test. The
50% inhibitory concentration (IC50) value was calculated
using Prism program (GraphPad Software Inc., La Jolla, CA,
USA).
3. Results
3.1. Na+-Dependent Glucose Uptake and SGLT1 Expression in
BBMV. The intestinal glucose uptake inhibitory activity of
EC extract was determined by in vitro model of BBMV using
2-NBDG. Na+-dependent 2-NBDG uptake by normal mice
intestinal BBMV was time- and concentration-dependent
and almost linear up to 15min and 200μg/mL (Figures 1(a)
and 1(b)). The uptake of 2-NBDG into the intestinal
BBMV showed a typical overshoot reaching its peak at
15min (Figure 1(a)). The overshoot was not observed in4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Glucose-stimulated insulin secretion in pancreatic islet
cells. The incubations were performed with or without EC extract
(50μg / m L )i n3 ,8 ,o r1 6m Mg l u c o s em e d i a .∗Signiﬁcant eﬀect of
mediaglucoseconcentrationand +signiﬁcanteﬀectofECtreatment
at P<0.05.
the presence of phlorizin, a SGLT1 inhibitor. These results
suggest that intestinal glucose uptake mediated by SGLT1
actively occurs after glucose ingestion reaching its peak
shortly,andSGLT1inhibitorabolishedtheactiveuptakeafter
glucose ingestion. Furthermore, in the presence of phlorizin,
glucose uptake was very low showing about 22% of the total
glucose uptake at 15min indicating that BBMV used SGLT1
as a major mechanism for glucose uptake. EC extract at
100μg/mL signiﬁcantly suppressed the Na+-dependent glu-
cose uptake into the BBMV in the entire uptake proﬁle
(Figure 1(a)). The inhibitory eﬀectswere 14, 22, 24, and 22%
at 5, 15, 30, and 40min incubation, respectively. The Na+-
dependent glucose uptake inhibitory activity of BBMV with
various concentrations of EC extract exhibited a dose depen-
dency with IC50 at 345 ± 54μg/mL (Figure 1(b)).
The abundance of SGLT1, measured by ELISA analysis,
wasdownregulatedinadose-dependentmannerandshowed
31.4%reductionwith200μg/mLECtreatment(Figure 1(c)).
3.2.Glucose-InducedInsulinSecretioninβ-IsletCells. Figure 2
shows the stimulatory eﬀect of the EC extract on insulin sec-
retioninthepresenceofglucose(3∼16mM).Glucoseinduc-
ed a dose-dependent increase of insulin secretion from pan-
creatic β-islet cells in both control and EC-treated group. In
thepresenceof16mMglucose,insulinsecretionincreasedby
2.9- and 10.4-fold compared to the 3mM glucose media in
control and EC-treated group, respectively. EC extract fails
to stimulate insulin output in 3∼8mM glucose media. How-
ever, EC extract signiﬁcantly boosted insulin secretion in
16mM glucose media exhibiting 2.8-fold increase as com-
pared with control group.
3.3. Intestinal Glucose Uptake in Diabetic Mice. To validate
the in vitro results, the antihyperglycemic eﬀects of EC sup-
plementation were investigated in STZ-induced diabetic
mice. Induction of diabetes caused signiﬁcant weight loss
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Figure 3: Eﬀect of Ecklonia cava (EC) on oral glucose tolerance.
Glucose(1.5g/kg)wasadministratedattimezeroafter12hourfast-
ing. Normal control mice (NC); normal mice supplemented with
EC powder for 4 weeks (NE); STZ-diabetic control mice (DC); dia-
betic mice supplemented with EC powder (DE). Values are mean ±
SE of 10 mice in each group. ∗Signiﬁcantly diﬀerent from normal
mice and +signiﬁcant eﬀect of EC treatment at P<0.05.
resulting in negative body weight gain, whereas EC con-
sumption for 4 weeks ameliorated weight loss (Table 1). The
Na+-dependentglucoseuptakebyBBMVpreparedfromdia-
betic mice was increased by 39.7% compared with normal
mice, and EC supplementation reduced the Na+-dependent
g l u c o s eu p t a k et on e a rn o r m a lv a l u e .I nn o r m a lm i c e ,E C
supplementation slightly (14.8%) reduced the Na+-depen-
dent glucose uptake without statistical signiﬁcance. SGLT1
expression in BBMV was 2.6-fold increased in diabetic mice
compared to normal mice. Consumption of EC reduced the
SGLT1 protein expressions by 17% and 34% in normal and
diabetic mice, respectively, conﬁrming the in vitro results.
T h ef a s t i n gb l o o dg l u c o s ec o n c e n t r a t i o n sw e r em a r k e d l yd e -
creased by EC supplementation in diabetic mice without any
signiﬁcant diﬀerences in normal mice. Plasma insulin con-
centrations were markedly reduced in diabetic mice, and EC
supplementation signiﬁcantly increased the plasma insulin
level reaching 75% of the normal insulin level. However, EC
supplementation did not aﬀect the plasma insulin concen-
trations in normal mice.
The oral glucose tolerance test (OGTT) can be used to
evaluatebloodglucosehomeostasisandalsoindirectlyevalu-
ate glucose absorption. As shown in Figure 3,g l u c o s el o a di n
normal mice produced rapid increase in blood glucose levels
from 108 ± 4 to 245 ± 15mg/dL at 30min and returned to
baseline values within 90min. In contrast, STZ-induced
diabetic mice demonstrated basal hyperglycemia (399 ±
14mg/dL) which remained above 400mg/dL during all time
points determined. The peak increase in serum glucose con-
centrationsindiabeticmicewasobservedafter60minofglu-
cose treatment, while that of normal mice observed after
30min, indicating delayed glucose homeostasis in diabetic
mice. Consumption of EC powder slightly reduced fasting
bloodglucoselevelinnormalmicewithoutanystatisticalsig-
niﬁcance. However, EC supplementation in diabetic miceEvidence-Based Complementary and Alternative Medicine 5
Table 1: Eﬀect of Ecklonia cava (EC) on blood glucose regulation.
NC NE DC DE
Body weight gain (g) 7.8 ± 0.9a 8.4 ± 0.6a −5.9 ± 0.7b −2.1 ± 0.4c
Glucose uptake1 357 ± 28a 304 ± 17a 499 ± 33b 392 ± 22a,c
SGLT1 expression2 1.00 ± 0.21a 0.83 ± 0.22a 2.61 ± 0.34b 1.72 ± 0.20c
Blood glucose (mg/dL) 112 ± 10a 109 ± 1a 395 ± 13b 240 ± 19c
Plasma insulin (ng/mL) 1.28± 0.03a 1.25± 0.03a 0.50 ± 0.01b 0.96 ± 0.03c
Values are means ± SE of 10 mice in each group. NC: normal control mice; NE: normal mice supplied with EC powder (3%). DC: STZ-mice; DE: STZ-mice
supplied with EC. 1Na+-dependent glucose uptake by BBMV was expressed as ﬂuorescence intensity. 2Relative SGLT1 protein expression.
a–cDiﬀerent superscript letter means signiﬁcantly diﬀerent at P<0.05.
dramatically decreased fasting blood glucose level, and post-
prandial glucose tolerance showed deﬁnite improvement ex-
hibiting similar pattern as normal mice with peak increase at
30min.
4. Discussion
The importance of postprandial glucose control in the de-
velopment of diabetic complications is widely recognized
based on many epidemiological studies. Several inhibitors of
α-amylase or β-glucosidase were proposed to control post-
prandial hyperglycemia, but the inhibitors of these enzymes
arenotabletopreventglucoseabsorptionwhenglucoseitself
has been ingested. Hence, it might be important to inhibit
intestinal glucose absorption as well as glucosidase or amyl-
ase activity for the regulation of postprandial blood glucose
level.
The capacity of the small intestine to absorb glucose in-
creases in patients with type 2 diabetes and in experimentally
induced diabetic animals as a consequence of the enhanced
activity and abundance of SGLT1 [2, 3] suggesting SGLT1 as
a potential target of drug development for glycemic control
in diabetic patients.
In the present study, we conducted an in vitro study to
examine the eﬀects of EC on intestinal glucose uptake using
BBMV. The results revealed that EC reduced SGLT1 activity,
assessed by Na+-dependent glucose uptake and SGLT1 pro-
tein expression in BBMV. Furthermore, the insulinotrophic
eﬀect of EC extract was observed at high glucose (16mM)
environment. Compared to the results at 3mM media glu-
cose, insulin secretion at 16mM glucose with EC extract in-
creased by 10.4-fold. This is consistent with the observation
that glucose acts synergistically with antidiabetic plant to
promote insulin secretion [13]. The elevated insulin secre-
tion with EC treatment at high glucose environment agrees
with in vivo results in Table 1, thus strengthening the evi-
dence that the EC acts as a stimulator of insulin secretion.
Diabetic mice (blood glucose > 20mM) markedly increased
plasma insulin concentration by 192% while Na+-dependent
glucose uptake was reduced by 22% in response to EC sup-
plementation. These results suggest that the relative contri-
bution of increased islet cell insulin secretion is more potent
than reduced intestinal Na+-dependent glucose uptake for
the regulation of blood glucose level in EC-supplemented
diabetic mice. Therefore, it is signiﬁcant that the EC extract
could potentiate insulin secretion at higher glucose concen-
tration, which could be useful in situations where chronic
hyperglycemia decreases the sensitivity of β-islet cells to glu-
cose-induced insulin secretion [14].
We subsequently examined the in vivo eﬀect of EC on
glucose uptake by BBMV prepared from STZ-diabetic mice
fed EC diet. Recent studies have shown that modiﬁcations of
systemic glycemia in OGTT reﬂect the activity of the intesti-
nal glucose transporter SGLT1 [15]. STZ-induced diabetic
mice exhibited severe hyperglycemia with increased Na+-
dependent glucose uptake activity and SGLT1 expression in
intestinal BBMV compared with normal mice. EC consump-
tion reduced intestinal Na+- d e p e n d e n tg l u c o s eu p t a k ea n d
SGLT1 expression in diabetic mice resulting in improvement
of OGTT and blood glucose level. The blood glucose and
insulin levels in EC supplemented mice were not completely
normalized whereas the intestinal Na+-dependent glucose
uptake was normalized, again suggesting the importance of
pancreatic insulin secretion for the regulation of blood glu-
cose homeostasis. The enhancement of intestinal glucose up-
take in diabetic mice might be attributed to several factors,
such as an increase in mucosal mass, an increase in the turn-
over of the transporter, and/or an increase in the number of
SGLT1. It has been reported that glucose transporter levels
including SGLT1 are elevated in diabetic animals and hu-
mans [2, 3].
Administration of EC suppressed the body weight loss in
diabetic mice suggesting that EC treatment may beneﬁcially
aﬀect the metabolic state in diabetes. Indeed, it has been re-
ported that administration of phlorizin or T-1095, Na+-de-
pendent glucose transporter inhibitor, leads to a body weight
gain in STZ diabetic rats [16, 17].
Seaweeds contain appreciable amounts of polyphenols,
and Ahn et al. [18] reported that the content of polyphenols
in EC is about 18.3%. It has been suggested that polyphenols
modulate hyperglycemia through various mechanisms. First,
glucose absorption from intestine was reduced by inhibiting
α-glucosidase and/or SGLT1 activity. Catechin [19], ﬂavo-
noid [20], and quercetin [21] have been reported to inhibit
α-glucosidase activity via steric hindrance. The inﬂuence of
polyphenolsonglucosetransportershasbeenstudiedinvitro
by using intestinal BBMV or everted sacs and Caco-2 cells.
The Na+-dependent SGLT1-mediated glucose transport was
inhibited by tea catechins [22, 23], tannic acids [24], and
quercetin monoglucosides [25]. Kobayashi et al. [22]a n d
Shimizu et al. [23] reported that green tea polyphenols,6 Evidence-Based Complementary and Alternative Medicine
especially epicatechin gallate (ECg), inhibit SGLT1 in a com-
petitive manner interacting as antagonist-like molecules,
althoughECgitselfwasnottransportedviatheglucosetrans-
porters. Oliveira et al. reported that polyphenol-rich Yerba
mat´ e decreased intestinal SGLT1 expression in alloxan-in-
duced diabetic rats [26]. Second, polyphenols increase pan-
creatic insulin secretion. Soy isoﬂavonoids (genistein and
daidzein)preservedinsulinproductionbytheβ-cellsinSTZ-
induced diabetic mice [27]. EGCG activates IRS2 and AMPK
signalling in rat pancreatic β-cells [28]. Genistein augments
cAMP accumulation and insulin release in MIN6 cells [29].
Therefore, it is obvious that the pancreas is one of the tar-
gets of dietary polyphenol bioactivity although no single
mechanism has been identiﬁed to be responsible for the res-
ponse.Althoughtheidentityofchemicalcomponentrespon-
sible for the antidiabetic action of EC in present study is un-
known, it would be of considerable interest to further elu-
cidate the mechanism and component(s) underlying the
action of EC.
In conclusion, this study demonstrates that EC manifests
two important antidiabetic properties: the inhibition of
intestinal Na+-dependent glucose absorption mediated by
reduced expression of SGLT1 and the stimulation of insulin
secretion in hyperglycemic environment, resulting in im-
provement of the glucose regulation in diabetic condition.
The present ﬁndings identify, for the ﬁrst time to our know-
ledge, the inhibitory eﬀect on intestinal glucose uptake and
insulinotrophic eﬀect of EC.
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